Incyte to Present at Upcoming Investor Conference

Incyte Corp (INCY) Q1 2024 Earnings Call Transcript Highlights: Strategic Acquisitions and Robust Revenue Growth

Q1 2024 Incyte Corp Earnings Call Transcript

Incyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in Clinical Programs

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

The past three years for Incyte (NASDAQ:INCY) investors has not been profitable

Certain Biotech Investors Get an Early Look at Results. Is That Fair?

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Novartis (NVS) to Undertake Job Cuts in Development Department

Incyte to Report First Quarter Financial Results

Incyte to Report First Quarter Financial Results

Agilent (A) is Set for Analytica 2024 With Advanced Products

Biotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says

SEC Wins Novel ‘Shadow’ Insider Trading Trial Against Executive

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive